Growing evidence propose an association between miRNA polymorphisms and cancer
susceptibility. This study aimed to examine the impact of miR-605 rs2043556 polymorphism on cancer
risk through a meta-analysis based on 3198 cancer cases and 4943 controls. Eligible studies were
retrieved by searching Web of Science, PubMed, Scopus, and Google Scholar databases up to August
27, 2018. The pooled Odds Ratios (ORs) with 95% Confidence Intervals (CIs) were calculated
using a random-effect model to estimate the strength of association between rs2043556 variant of
miR-605 and cancer risk. Overall, no significant association was found between miR-605 rs2043556
polymorphism and cancer risk in heterozygous codominant (OR=0.93, 95% CI=0.76-1.13, p=0.44,
AG vs. AA), homozygous codominant (OR=1.01, 95%CI=0.78-1.30, p=0.94, GG vs. AA), dominant
(OR=0.95, 95% CI=0.79-1.13, p=0.55, AG+GG vs. AA), recessive (OR=1.07, 95%CI=0.84-1.38,
p=0.57, GG vs. AG+AA), overdominant (OR=0.93, 95% CI=0.76-1.12, p=0.43, AG vs. GG+AA),
and allele (OR=0.98, 95% CI=0.87-1.10, p=0.73, G vs. A) genetic models tested. Stratified analysis
by cancer type revealed that the rs2043556 variant was not associated with digestive tract cancer,
breast cancer, gastric cancer as well as lung cancer.
Taken together, the findings of this meta-analysis did not support an association between miR-605
rs2043556 polymorphism and cancer susceptibility.